Article information
Resumen
Las personas con síndrome de Down (SD), en especial durante su infancia, presentan una particular predisposición a padecer infecciones, debido sobre todo a la asociación del síndrome con una inmunodeficiencia primaria multifactorial. Un buen número de estas enfermedades son susceptibles de vacunación. Los estudios sobre vacunaciones en el SD son escasos y no incluyen los preparados inmunizantes más recientes. A falta de que se corrijan estas insuficiencias, los conocimientos actuales permiten sostener que las vacunas actualmente disponibles son seguras e inmunógenas en la población Down, aunque posibles respuestas algo inferiores a las habituales obligan al estricto cumplimiento de las pautas vacunales establecidas para asegurar su efectividad.
Palabras clave:
Síndrome de Down
Inmunización activa
Vacunaciones
Inmunización pasiva
Abstract
People with Down syndrome (DS) are especially infection-prone, particularly during childhood. The main reason is an association of DS with multifactorial primary immune deficiency. Many of these conditions are immunizable, but studies of vaccination and DS are few and do not include recent formulations. While awaiting remediation of this gap, the present state of knowledge is that available vaccines are safe and effective for people with DS, though the possibility that response may be lower than average means that strict compliance with immunization schedules is required to ensure effectiveness.
Keywords:
Down syndrome
Active immunization
Vaccination
Passive immunization
Full text is only aviable in PDF
Bibliografía
[1.]
A. Martín-Mateos.
Inmunidad en el síndrome de Down.
Síndrome de Down. Aspectos médicos actuales, pp. 109-117
[2.]
L. Nespoli, G.R. Burgio, A.G. Ugazio, R. Maccario.
Immunological features of Down's syndrome: a review.
J Intel Disabil Res, 37 (1993), pp. 543-551
[3.]
Y.C.M. De Hingh, P.W. van der Vossen, E.F.A Gemen, et al.
Intrinsic abnormalities of lymphocyte counts in children with Down Syndrome.
J Pediatr, 147 (2005), pp. 744-747
[4.]
B. Breuer, S.M. Friedman, E.S. Millner, et al.
Transmision of Hepatitis B virus to classroom contacts of mentally retarded carriers.
JAMA, 254 (1985), pp. 3190-3195
[5.]
M. García Bengoechea, J.J. Legarda, A. Cortés, et al.
Los deficientes mentales y la infección por el virus de la hepatitis B. Prevalencia en nuestro medio.
Med Clin (Barcelona), 93 (1989), pp. 10-13
[6.]
J. Arístegui-Fernández, R. Cisterna-Cáncer, J. Muñiz-Saitua, et al.
Prevalencia de infección por el virus de la hepatitis B en instituciones de deficientes mentales. Características epidemiológicas en la provincia de Vizcaya.
Med Clin (Barcelona), 92 (1989), pp. 323-327
[7.]
M.J. Rua-Armesto, V. Ramírez-Marín, M.T. Onaindia-Ercoreca, et al.
Predisposición del síndrome de Down a la infección crónica por el virus B de la hepatitis.
An Esp Pediatr, 38 (1993), pp. 529-531
[8.]
V. Di Ciommo, F. Ferrario, M. Rossi de Gasperi, et al.
Epidemiology of hepatitis B virus in non institutionalized children and adolescents affected by handicap.
J Intel Disabil Res, 37 (1993), pp. 295-299
[9.]
M. Wahl, S. Hermodason, S. Iwarson.
Immune response to hepatitis B vaccine in the mentally retarded.
J Infect, 7 (1983), pp. S47-S51
[10.]
O. García, M. Bruguera, J.M. Mayor, et al.
Hepatitis B en una institución abierta para retrasados mentales. Efecto inmunogénico de una vacuna recombinante antihepatitis B.
Enf Inf Microbiol Clin, 8 (1990), pp. 148-152
[11.]
S. Krugman.
Hepatitis B carriers in the classroom (Editorial).
JAMA, 254 (1985), pp. 3218-3219
[12.]
M.A. Avanzini, V. Monafo, M. De Amici, et al.
Humoral immunodeficiencies in Down Syndrome: Serum IgG subclass and antibody response to hepatitis B vaccine (Letter to the Editor).
Am J Med Genet, (1990), pp. 231-233
[13.]
M. Piccione, M. De Curtis, M.L. La Vecchia, et al.
Hepatitis B and C infection in children with Down syndrome.
Eur J Pediatr, 156 (1997), pp. 420-421
[14.]
R. Ward, P. Borchert, A. Wright, E. Kline.
Hepatitis B antigen in saliva and mouth washings.
Lancet, 2 (1972), pp. 726-727
[15.]
C.L. Troisi, D.A. Heiberg, F. Blaine Hollinger.
Normal immune response to Hepatitis B vaccine in patients with Down Syndrome. A basis for immunization guidelines.
JAMA, 254 (1985), pp. 3196-3199
[16.]
J. Cobo-Soriano, A. Gil-Miguel, J. Rey-Calero, et al.
Inmunogenicidad de la vacuna contra el VHB en deficientes mentales.
At Primaria, 8 (1991), pp. 536-541
[17.]
P. Van Damme, R. Vranckx, A. Meheus.
Immunogenicity of a recombinant DNA hepatitis B vaccine in institutionalized patients with Down's syndrome.
Vaccine, 8 (1990), pp. S53-S55
[18.]
M. García-Bengoechea, E. Cortés, J. Cabriada, et al.
Respuesta a la vacuna DNA recombinada antihepatitis B en los deficientes mentales con síndrome de Down. Estudio controlado.
Med Clin (Barcelona), 94 (1990), pp. 528-530
[19.]
P. Vajro, P. Letrera, A. Fontanella, et al.
Vaccination against hepatitis B in preschool children with Down's syndrome.
J Intel Disabil Res, 36 (1992), pp. 77-81
[20.]
M.A. Avanzini, T. Söderström, M. Wahl, et al.
IgG subclass deficiency in patients with Down's syndrome and aberrant hepatitis B vaccine response.
Scand J Immunol, 28 (1988), pp. 465-470
[22.]
J.M. Corretger, R. Baraibar.
Vacunaciones en niños con enfermedades crónicas.
Vacunaciones en el niño. De la teoría a la práctica, pp. 880-882
[23.]
C.T. Ferreira, J.C. Leite, A. Taniguchi, et al.
Immunogenicity and safety of an inacivated hepatitis A vaccine in children with Down syndrome.
Pediatr Gastroenerol Nutr, 39 (2004), pp. 337-340
[24.]
M.M. Garrison, H. Jeffries, D.A. Christakis.
Risk of death for children with Down syndrome and sepsis.
J Pediatr, 147 (2005), pp. 748-752
[25.]
T. Nurmi, M. Leinonen, V.M. Haiva, et al.
Antibody response to pneumoccoccal vaccine in patients with trisomy-21 (Down's syndrome).
Clin Expo Immunol, 48 (1982), pp. 485-490
[26.]
B.T. Costa-Carvalho, R.M.A. Martinez, A.T.N. Dias, et al.
Antibody response to pneumococcal capsular vaccine in Down syndrome patients.
Braz J Med Res, 39 (2006), pp. 1587-1592
[27.]
R. Philip, A.C. Berger, N.H. McManus, et al.
Abnormalities of the in vitro cellular and humoral responses to tetanus and influenza antigens with concomitant numerical alterations in lymphocyte subsets in Down syndrome (trisomy 21).
J Immunol, 136 (1986), pp. 1661-1667
[28.]
M.G. Gordon, S.K. Sinha.
Antibody responses to influenza vaccine in patients with Down's syndrome.
Am J Ment Def, 75 (1971), pp. 391-399
[29.]
R.A. Hawkes, C.R. Boughton, D.R. Shroeter.
The antibody response of institutionalized Down's syndrome to seven microbial antigens.
Clin Exp Immunol, 31 (1978), pp. 298-304
[30.]
A.W. Griffiths, P.E. Sylvester.
Mongols and nonmongols compared in their response to active tetanus immunisation.
J Ment Def Res, 11 (1867), pp. 263-266
[31.]
S. LiVolti, T. Mattina, L. Mauro, et al.
Safety and effectiveness of an acellular pertussis vaccine in subjects with Down's syndrome.
Childs Nerv Syst, 12 (1996), pp. 100-102
[32.]
R.A. Hawkes, S.C. Philbrook.
The response of institutionalized Down's syndrome subjects to enterovirus infections.
J Hyg, 84 (1980), pp. 433-441
[33.]
B.LP. Bloemers, M. van Furth, M.E. Weijerman, et al.
Down Syndrome: A novel risk factor for Respiratory Syncitial Virus bronchiolitis – A prospective Birth-Cohort study.
Pediatrics, 120 (2007), pp. 1076-1081
Copyright © 2008. FCSD. All rights reserved